| (Values in U.S. Thousands) | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 | Jun, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -8,320 | -14,650 | -22,660 | -38,300 | -9,130 |
| Net Income Growth | +43.21% | +35.35% | +40.84% | -319.50% | -13.42% |
Kintara Therapeutics Inc (KTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kintara Therapeutics Inc. is a biopharmaceutical company. It is focused on the development of new solid tumor cancer therapies. The company's program includes VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer, which are in clinical stage. Kintara Therapeutics Inc. is based in San Diego, California.